Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Aptevo Therapeutics (APVO) Net Margin (2016 - 2022)

Aptevo Therapeutics (APVO) has disclosed Net Margin for 8 consecutive years, with 5.72% as the latest value for Q1 2022.

  • Quarterly Net Margin fell 1138.0% to 5.72% in Q1 2022 from the year-ago period, while the trailing twelve-month figure was 32.53% through Dec 2022, up 2479.0% year-over-year, with the annual reading at 32.53% for FY2022, 2479.0% up from the prior year.
  • Net Margin hit 5.72% in Q1 2022 for Aptevo Therapeutics, down from 8.87% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 47.16% in Q3 2019 to a low of 34.49% in Q4 2019.
  • Historically, Net Margin has averaged 2.23% across 5 years, with a median of 3.41% in 2021.
  • Biggest five-year swings in Net Margin: plummeted -56451bps in 2018 and later skyrocketed 4649bps in 2019.
  • Year by year, Net Margin stood at 0.67% in 2018, then tumbled by -5251bps to 34.49% in 2019, then soared by 114bps to 4.97% in 2020, then surged by 78bps to 8.87% in 2021, then crashed by -36bps to 5.72% in 2022.
  • Business Quant data shows Net Margin for APVO at 5.72% in Q1 2022, 8.87% in Q4 2021, and 2.58% in Q3 2021.